Crystalline Glucosylceramide Synthase Inhibitor Forms for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a stable form of the glucosylceramide synthase inhibitor (Compound 1) with advantageous chemical and physical properties to ensure quality, safety, and efficacy in pharmaceutical applications.
Innovation Solution
The development of various crystalline forms of Compound 1, including anhydrate, hydrate, solvates, and salts, characterized by specific X-ray powder diffraction patterns, to provide stability and reproducibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a stable crystalline form of Compound 1 is selected for drug development, then chemical stability and manufacturing reproducibility are improved, but the selection process requires extensive characterization and validation time
Solution Approach 1:
The patent performs preliminary identification and characterization of multiple crystalline forms (Forms A-E) and their salts during the early drug development stage. By pre-characterizing XRPD patterns, DSC curves, and stability profiles of different crystalline forms before clinical trials begin, the invention reduces the time required for crystalline form selection and validation during later development phases.
Solution Approach 2:
The patent systematically varies crystallization parameters (solvent type, temperature, pH, concentration) to generate and identify multiple crystalline forms with different stability characteristics. This approach allows the selection of the most stable form (Form A) with optimized physicochemical properties, balancing stability improvement with efficient characterization.
2Reliability
If multiple crystalline forms are characterized to ensure quality and efficacy, then drug quality and reliability are improved, but the complexity of characterization and analysis increases
Solution Approach 1:
The patent segments the crystalline form characterization into distinct, standardized modules: XRPD pattern identification (specific peak positions), DSC thermal analysis (melting points, phase transitions), solubility measurements, and stability testing. This modular approach allows systematic evaluation of each crystalline form using established protocols, reducing overall characterization complexity while ensuring comprehensive quality assessment.
Solution Approach 2:
The patent replaces complex, time-consuming manual characterization methods with instrumental analysis techniques. XRPD provides rapid crystal structure identification through diffraction patterns, DSC automatically measures thermal properties, and HPLC quantifies purity and solubility. These instrumental substitutions reduce human effort and increase characterization efficiency while maintaining high reliability.
3Stability of the object's composition
If the most stable crystalline form is chosen for manufacturing, then product stability is improved, but manufacturing process optimization requires additional time and resources
Solution Approach 1:
The patent performs preliminary optimization of the crystallization process for Form A during the development phase, identifying optimal parameters (solvent composition, cooling rate, seeding conditions, pH control) that reliably produce the desired crystalline form. This pre-optimization ensures that manufacturing can proceed with established, validated parameters, reducing future process development requirements.
Solution Approach 2:
The patent uses crystallization intermediates and seed crystals as mediators to control the formation of Form A during manufacturing. By introducing pre-formed seed crystals of the desired polymorph or using controlled crystallization intermediates, the process reliably produces the stable Form A without requiring extensive real-time monitoring or adjustment during production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of Compound 1 exhibit enhanced chemical stability and favorable physicochemical properties, ensuring reliable drug production and efficacy in treating GCS-associated diseases.
Implementation Method 1
Crystalline Form A is characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks selected from the group consisting of about 18.883°, about 10.889°, and about 21.309° 2θ
Implementation Method 2
characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks
Data Source
AI summary
The present disclosure relates to crystalline forms of (E)-N-((1R,2R)-1-(3-chloro-4-cyclopropoxyphenyl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-2-(6-chloronaphthalen-2-yl)-2-(hydroxyimino)acetamide, the method of preparing the forms, pharmaceutical compositions comprising the forms, and uses thereof.